• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?
【24h】

Methoxy polyethylene glycol-epoetin beta: worth waiting for or a novelty worn off?

机译：甲氧基聚乙二醇-表皮素β：值得期待还是值得淘汰？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Since their inception nearly two decades ago, erythropoietin-stimulating agents (ESAs) have revolutionized the care of patients with renal anemia. Until recently, treatment options included the epoetins and darbepoetin alfa. As the use of these agents for chronic kidney disease (CKD) became widespread, the introduction of ESAs--touted for their longer-acting properties--was excitedly anticipated. OBJECTIVES: To review the option of methoxy polyethylene glycol-epoetin beta for ESA therapy in patients with renal anemia. METHODS: Peer-reviewed scientific literature, published abstracts and renal business journals were reviewed in the writing of this opinion. RESULTS/CONCLUSION: Methoxy polyethylene glycol-epoetin beta (CERA) is an effective long-acting ESA approved for treatment of renal anemia and available for use outside of the United States. CERA corrects and maintains hemoglobin (Hb) levels in patients with CKD and its efficacy mirrors that of the epoetins and darbepoetin alfa. CERA holds promise for its safety record, administration requirements, and the potential impact on social and pharmacoeconomic barriers to treatment for patients with renal anemia.
机译：背景：促红细胞生成素刺激剂（ESA）自将近20年前问世以来，就彻底改变了肾性贫血患者的护理方法。直到最近，治疗方案还包括依泊汀和阿尔法达泊汀。随着这些药物用于慢性肾脏疾病（CKD）的广泛使用，人们兴奋地期望引入ESA（因其更长效的特性而被吹捧）。目的：审查甲氧基聚乙二醇-表皮素β在肾性贫血患者的ESA治疗中的选择。方法：在撰写此意见时，对同行评议的科学文献，发表的摘要和肾脏业务期刊进行了综述。结果/结论：甲氧基聚乙二醇-表皮素β（CERA）是一种有效的长效ESA，已获批准用于治疗肾性贫血，可在美国以外的地区使用。 CERA可以纠正和维持CKD患者的血红蛋白（Hb）水平，其疗效与依泊汀和darbepoetin alfa相近。 CERA的安全记录，给药要求以及对肾性贫血患者治疗的社会和药物经济障碍的潜在影响都具有希望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号